Payward Secures VARA Authorization in UAE, Enabling Kraken to Expand Regional Presence

Kraken to offer UAE clients dirham funding, trading pairs and direct access to global liquidity

(BUSINESS WIRE) -- Payward, a unified financial infrastructure platform and the parent company of Kraken, today announced its expansion into the United Arab Emirates after being granted preliminary approval for a broker-dealer, investment and management licence from the Virtual Asset Regulatory Authority (VARA) in Dubai, UAE.

Kraken, one of the world’s longest-standing and most liquid cryptocurrency platforms, now has the regulatory go-ahead to offer a full range of services in Dubai. This will include spot, margin, and OTC trading, staking, and access to Kraken Prime for institutional clients, as well as crypto transfers between users through Krak.

UAE traders will be able to access Kraken’s global orderbooks, which have deep liquidity and reliable execution across major markets in Europe, the US, and APAC. Through a locally regulated Payward subsidiary, clients will also be able to fund and withdraw in dirhams (AED), giving secure, frictionless access to global crypto markets through a trusted, regulated on-ramp.

“Dubai wrote a rulebook for crypto before most jurisdictions even acknowledged the asset class,” said Arjun Sethi, Co-CEO of Payward and Kraken. “That clarity is why real liquidity and institutional capital now sit in the UAE. Operating under VARA puts Kraken inside that perimeter, serving clients through a local, supervised entity rather than from offshore.”

This launch is part of Payward’s broader global growth strategy to establish regulated, on-the-ground operations in key financial centers. By connecting new markets to its core trading network, Kraken gives clients access to premium execution, deep liquidity and a consistent high standard of service worldwide.

Sethi continued: “Clients in the UAE get the same order book, the same balance sheet, and the same multi-asset coverage we run in every other market. The difference is the rulebook is written down and the supervisor is local. That is what a license should mean.”

Kraken will introduce its Buy, Trade and Earn products to the UAE, offering direct access to spot trading and staking, subject to regulatory approval. Over time, Kraken will expand its offering to include derivatives, lending and new investment products for qualified clients.

About Payward

Payward, Inc. is a unified financial infrastructure platform that powers a family of products advancing an open, global financial system. Built on a single shared architecture, Payward enables customers to hold, trade, earn, pay, and invest across asset classes without friction or fragmentation.

At its core, Payward provides the infrastructure layer behind Kraken and a growing set of purpose-built products, including NinjaTrader, Breakout, xStocks, and CF Benchmarks.

Payward separates infrastructure from product expression. Each product surface is designed for a specific customer segment, regulatory regime, and use case, while operating on the same global foundation:

• One global liquidity pool

• One unified risk and margin engine

• One collateral and settlement system

• One compliance and licensing framework

This shared architecture allows Payward to scale efficiently, launch new products at low marginal cost, and serve diverse global markets while maintaining consistent risk management, regulatory integrity, and operational resilience.

For more information about Payward, please visit www.payward.com

About Kraken

Founded in 2011, Kraken is one of the world’s longest-standing and most secure crypto platforms globally. Kraken clients trade more than 600 digital assets, traditional assets such as U.S. futures and U.S.-listed stocks and ETFs, and 6 different national currencies, including GBP, EUR, USD, CAD, CHF, and AUD. Trusted by millions of institutions, professional traders and consumers, Kraken is one of the fastest, most liquid and performant trading platforms available.

Kraken’s suite of products and services includes the Kraken App, Kraken Pro, the Krak App, Kraken Institutional, Kraken’s onchain offerings and the Ninja Trader retail trading platform. Across these offerings, clients can buy, sell, stake, earn rewards, send and receive assets, custody holdings, and access advanced trading, derivatives, and portfolio management tools.

Kraken has set the industry standard for transparency and client trust, and it was the first crypto platform to conduct Proof of Reserves. It complies with regulations and laws applicable to its business, while actively protecting client privacy and maintaining the highest security standards.

For more information about Kraken, please visit www.kraken.com.

Regulatory Disclosure

Payward FZCO is licensed by the Virtual Assets Regulatory Authority (VARA) as a Virtual Asset Service Provider (VASP) under [License Category: Broker-Dealer / Investment and Management, full license reference upon final issuance]. This authorization permits the provision of virtual asset services to both retail and professional investors in the Emirate of Dubai, subject to VARA's regulatory framework and applicable conditions.

Services available to retail clients are limited to those expressly permitted for retail clients under VARA's retail-access rules and may differ from products and services available to professional clients.

Virtual assets are inherently risky and may lose value. Retail clients should carefully review the applicable risk disclosures and ensure they understand the nature of virtual asset exposures before trading. Payward maintains segregated client asset arrangements and regulatory capital requirements as prescribed by VARA.

This press release does not constitute an offer, solicitation, or investment advice. Product availability is subject to local regulatory approval and may vary by jurisdiction. For full regulatory status and client categorization details, visit https://www.kraken.com/legal/disclosures.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521552844/en/

Permalink
https://aetoswire.com/en/news/2105202655226

Contacts

Lauren Post
press@kraken.com

Audiencerate: انضمام Riccardo Fabbri بمنصب الرئيس التنفيذي للتكنولوجيا — بدء المرحلة المدعومة بالذكاء الاصطناعي لمنصات الشركات الصغيرة والمتوسطة ووكالات الإعلام

 

 سيقود المؤسس المشارك والشريك الإداري السابق لشركة Nohup (التي استحوذت عليها Havas Group في عام 2021) تطوير البنية التحتية للذكاء الاصطناعي التي تدمج بيانات الطرف الأول وبيانات الطرف الثالث، مما يدعم المنصة المقدمة مع Postel وMicrosoft للشركات الصغيرة والمتوسطة الإيطالية والمنصة مع عرض DV360 لوكالات الإعلام العالمية.

(BUSINESS WIRE)-- أعلنت شركة Audiencerate Ltd، وهي واحدة من الشركاء المعتمدين عالميًا في Google Customer Match Upload Partners وشريك معتمد من Microsoft IP Co-sell مع أهلية MACC، اليوم عن تعيين Riccardo Fabbri في منصب الرئيس التنفيذي للتكنولوجيا. يمثل هذا التعيين مرحلة من التوسع المزدوج: منصة Audiencerate–Postel–Microsoft للشركات الصغيرة والمتوسطة الإيطالية، ومنصة البيانات المتكاملة مع Google DV360 للوكالات ومقدمي البيانات - وكلاهما يتطور نحو نموذج يستفيد بشكل أصلي من بيانات الطرف الأول وبيانات الطرف الثالث من خلال الذكاء الاصطناعي والتعلم الآلي.

 خبرته تمتد لعشرين عامًا في مجال التحول الرقمي.

يتمتع Fabbri بخبرة تزيد عن عقدين من الزمن في تطوير البرمجيات وهياكل الحوسبة السحابية. شارك في تأسيس شركة Nohup في عام 2004، وهي شركة استشارات رقمية في مجال تطوير التطبيقات السحابية الأصلية، وقاد الشركة إلى الحصول على تقدير صحيفة Financial Times من بين الشركات الرائدة في أوروبا في هذا القطاع لمدة عامين متتاليين (2021 و2022). في أغسطس 2021، استحوذت مجموعة Havas Group على شركة Nohup، مما أدى إلى ضم 30 من محترفيها في ميلانو وتورينو وأوديني إلى Havas CX. إن السمة المميزة لمسار Fabbri هي الدقة الهندسية، والاهتمام بالخصوصية، والمعرفة العميقة بسير العمليات التشغيلية للوسائط - وهو أصل أساسي ضمن الإطار الأوروبي لقانون الذكاء الاصطناعي، واللائحة العامة لحماية البيانات، وقانون المستهلك الإيطالي.

 قفزة نوعية مدفوعة بالذكاء الاصطناعي للشركات الصغيرة والمتوسطة والوكالات

تحت قيادة Fabbri، ستُسرّع Audiencerate من وتيرة نموها على مسارين متوازيين. على صعيد الشركات الصغيرة والمتوسطة، يُمكّن الذكاء الاصطناعي والتعلم الآلي من التعلم المستمر للنماذج، والنمذجة التنبؤية (التصنيف حسب الميل، والتشابه، وقيمة العميل الدائمة) والتحسين الذاتي لإدارة الميزانية والعطاءات. أما على صعيد الوكالات، فإن بيانات الطرف الأول للمعلنين بمثابة نواة لنماذج التشابه والميل التي يتم إثراؤها بإشارات الطرف الثالث: جمهور يجمع بين ملاءمة الطرف الأول وحجم الطرف الثالث، بما يتوافق مع تطور الخصوصية ونظام ملفات تعريف الارتباط.

 كشوف الحسابات

قال Gianluca Leotta، رئيس Audiencerate: "إن مشاركة Riccardo هي القطعة المفقودة. إنه رائد أعمال تقني قاد شركة Nohup إلى الخروج الأوروبي، وعاش داخل عالم وكالات الإعلام الدولية، ويعرف القواعد التقنية لمسارنا بدقة. إنه خيار طويل الأمد، يتماشى مع الرؤية التراثية والصناعية التي لطالما تمسكنا بها لهذا المشروع".

وقال Riccardo Fabbri: "لقد قامت Audiencerate على مر السنين ببناء أصل تكنولوجي فريد من نوعه: وهو موقع مزود بيانات أصلي لكل من أنظمة Google وMicrosoft، مع شهادات وشراكات لا تستطيع سوى عدد قليل جدًا من الشركات ادعائها. المشروع يمثل تحديًا وإثارة في آن واحد. من ناحية، يتمثل في توفير هذه البنية التحتية لملايين الشركات الإيطالية الصغيرة والمتوسطة من خلال Postel وMicrosoft. ومن جهة أخرى، يهدف إلى تطوير عرض DV360 بالاستفادة من خبرة عشرين عامًا مع وكالات الإعلام: إذ تحتاج مكاتب التداول إلى نماذج تدمج بذكاء بيانات الطرف الأول وبيانات الطرف الثالث، مع السعي في الوقت نفسه إلى تحقيق الأتمتة والتوسع اللازمين لاستعادة هوامش الربح التي لم يعد السوق يعترف بها كما كان في السابق. هذا النوع من التحديات الهندسية ينسجم مع مسيرتي كمؤسس ورائد أعمال".

 حول Audiencerate

تتخصص شركة Audiencerate Ltd، التي يقع مقرها الرئيسي في لندن ولها مكاتب في إيطاليا والولايات المتحدة، في تفعيل البيانات، وذكاء الجمهور، والتسويق القائم على الذكاء الاصطناعي. وتعد الشركة شريكًا لـ Google Customer Match Upload Partner (ديسمبر 2025)، ومزود بيانات لـ Google منذ عام 2012، ومؤهلة لبرنامج البيع المشترك للملكية الفكرية من Microsoft (Microsoft IP Co-sell) / مؤهلة لبرنامج MACC. تُعدّ NEXI العميل المؤسسي الرئيسي للشركة في إيطاليا.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

 

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260519344995/en

الرابط الثابت

https://www.aetoswire.com/ar/news/2205202655246

جهات الاتصال

 جهات الاتصال بوسائل الإعلام:

 press@audiencerate.com · www.audiencerate.com

Audiencerate: Riccardo Fabbri Joins as Chief Technology Officer—The AI-Driven Phase of the Platforms for SMEs and Media Agencies Begins

 

The co-founder and former managing partner of Nohup (acquired by Havas Group in 2021) will lead the development of the artificial intelligence infrastructure that integrates first-party and third-party data, powering the platform delivered with Postel and Microsoft to Italian SMEs and the platform with the DV360 offering for global media agencies.

 

(BUSINESS WIRE)--Audiencerate Ltd, one of the few globally certified Google Customer Match Upload Partners and a Microsoft IP Co-sell certified partner with MACC eligibility, today announced the appointment of Riccardo Fabbri as Chief Technology Officer. The appointment marks a phase of dual expansion: the Audiencerate–Postel–Microsoft platform for Italian SMEs, and the Data platform integrated with Google DV360 for Agencies and Data Providers — both evolving toward a model that natively leverages first-party and third-party data through AI and machine learning.

A profile built on twenty years of digital transformation

Fabbri brings to Audiencerate over two decades of experience in software development and cloud architectures. Co-founder in 2004 of Nohup, a digital consultancy in cloud-native development, he led the company to Financial Times recognition among Europe's leading firms in the sector for two consecutive years (2021 and 2022). In August 2021 Nohup was acquired by the Havas Group, bringing its 30 professionals across Milan, Turin, and Udine into Havas CX. The distinctive trait of Fabbri's path is engineering rigor, attention to privacy, and deep knowledge of media operational workflows — an essential asset within the European framework of AI Act, GDPR, and the Italian Consumer Code.

The AI-driven leap for SMEs and Agencies

Under Fabbri's leadership, Audiencerate will accelerate on two parallel tracks. On the SME front, AI and machine learning enable continuous model learning, predictive modeling (propensity scoring, lookalike, CLV) and self-optimization of budget and bid management. On the agency front, advertisers' first-party data serves as seed for lookalike and propensity models enriched with third-party signals: an audience that combines 1P relevance with 3P scale, compliant with privacy and cookie ecosystem evolution.

Statements

"Riccardo's entry is the missing piece," said Gianluca Leotta, President of Audiencerate. "A technologist-entrepreneur who took Nohup to a European exit, lived inside the international media agency world, and knows the technical grammar of our trajectory exactly. It is a long-term choice, consistent with the patrimonial and industrial vision we have always had for this project."

"Audiencerate has built over the years a unique technological asset: a Data Provider position native to both Google and Microsoft ecosystems, with certifications and partnerships that very few companies can claim," said Riccardo Fabbri. "The project is both challenging and exciting. On one side, bringing this infrastructure to millions of Italian SMEs through Postel and Microsoft. On the other, evolving the DV360 offering by drawing on twenty years alongside media agencies: trading desks need models that intelligently fuse first-party and third-party data, while pursuing the automation and scale needed to recover margins the market no longer recognizes as it once did. This is the kind of engineering challenge that resonates with my path as a founder and entrepreneur."

About Audiencerate

Audiencerate Ltd, headquartered in London with offices in Italy and the United States, specializes in data activation, audience intelligence, and AI-driven marketing. Google Customer Match Upload Partner (December 2025), Google Data Provider since 2012, Microsoft IP Co-sell Eligible / MACC Eligible. NEXI is the company's flagship enterprise client in Italy.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519344995/en/

Permalink

https://www.aetoswire.com/en/news/2105202655215

Contacts

Media contact:

press@audiencerate.com · www.audiencerate.com

شركة AHS العقارية: عباس سجواني، 26 عامًا، يستثمر مليارات الدولارات في مستقبل دبي

 

 دبي، الإمارات العربية المتحدة - الخميس, 21. مايو 2026


يُعدّ مؤسس شركة AHS العقارية، والذي صنّفته مجلة فوربس أصغر ملياردير في قطاع العقارات على مستوى العالم، رائداً في تطوير مشاريع بقيمة 50 مليار درهم إماراتي، انطلاقاً من قناعة راسخة: لم تعد دبي سوقاً للرفاهية فحسب، بل أصبحت وجهة استثمارية عالمية.

 

بينما يشهد سوق العقارات العالمي إعادة تقييم، يُسرّع عباس سجواني وتيرة نموه.

يبني سجواني، المؤسس والرئيس التنفيذي لشركة AHS Properties، البالغ من العمر 26 عاماً، والذي صنّفته مجلة فوربس مؤخراً كأصغر ملياردير عربي وأصغر ملياردير في قطاع العقارات على مستوى العالم، بثروة صافية تبلغ 1.9 مليار دولار أمريكي، أحد أسرع منصّات التطوير العقاري نمواً في دبي.

فمنذ إطلاقها في عام 2021، توسعت شركة AHS Properties من إعادة تطوير الفيلات الفاخرة للغاية إلى محفظة بمليارات الدولارات تشمل مشاريع سكنية على الواجهة البحرية، ومشاريع تجارية من الدرجة الأولى، ومشاريع متعددة الاستخدامات واسعة النطاق عبر أهم الممرات الاستراتيجية في دبي.

هذا وقد حقق يقع برجها الرائد على شارع الشيخ زايد، مبيعات كاملة خلال فترة الإنشاء، بينما من المتوقع أن تصل قيمة مشاريعها المستقبلية إلى 50 مليار درهم إماراتي بنهاية العام.

ويستند هذا النمو إلى استراتيجية تخالف الحذر السائد في السوق.

يقول سجواني: "إن الخطر الحقيقي في هذا السوق ليس التقلبات، بل الانتظار. فبحلول الوقت الذي يصبح فيه اليقين واضحًا، تكون الفرصة قد تم تسعيرها بالفعل".

في الوقت الذي تراجعت فيه قطاعات من رأس المال العالمي وسط حالة من عدم اليقين الجيوسياسي والاقتصادي الكلي، واصلت AHS Properties التوسع، حيث تابعت عمليات الاستحواذ الاستراتيجية على الأراضي وأطلقت مشاريع جديدة تتماشى مع الطلب الطويل الأجل.

وحجَّة سجواني في هذا السياق بنيويّة وليست دوريّة.

فهو يعتقد أن دبي تشهد تحولاً جذرياً، من وجهة فاخرة إلى مركز محوري لرؤوس الأموال العالمية، مدفوعةً بتدفقات مستمرة من الأفراد ذوي الثروات الطائلة، والمؤسسين، والمكاتب العائلية.

 

يقول: "لا يتعلق الأمر بالطلب القصير الأجل، بل بالمكان الذي تختار رؤوس الأموال للازدهار".

يستند هذا المنظور إلى خبرة مبكرة في الأسواق المالية. فمنذ أن بدأ تداول الأسهم في سن الرابعة عشرة، طور سجواني نهجاً منضبطاً وطويل الأجل لتخصيص رأس المال، وهو نهج يُطبق الآن على نطاق واسع في قطاع العقارات.

مع إعادة المستثمرين العالميين تقييم استثماراتهم الجغرافية، تبرز شركة AHS Properties كشركة رائدة في مجال الاستثمار العقاري، لا تعتمد على توجهات السوق، بل تستشرفها.

 

للمزيد من المعلومات الإعلامية، تفضلوا بزيارة: https://ahsproperties.com/abbas-sajwani/

نبذة عن AHS Properties :  https://ahsproperties.com/


الرابط الثابت
https://www.aetoswire.com/ar/news/2105202655217

جهات الاتصال
تامي أتلي، مديرة الاتصالات: tammy.atlee@ahs-properties.com

سُرى حمادين، مسؤولة العلاقات العامة،  sura.hammadin@ahs-properties.com

ليلاس ألربد، مسؤولة الاتصالات،  lilas.alarbed@ahs-properties.com

Imagine Dragons, légendaire groupe d’Arena Rock, en tête d'affiche du Grand Prix d’Abou Dhabi

  

Dans une annonce majeure, Ethara, organisateur du spectaculaire Grand Prix de Formule 1 Etihad Airways d'Abou Dhabi, a confirmé que le légendaire groupe de rock, Imagine Dragons, assurera la tête d’affiche du concert d'après-course du samedi, lors de la grande finale de la saison de Formule 1 à Abou Dhabi — promettant une clôture de championnat aussi explosive que mémorable.

Cette annonce représente un moment phare pour le Grand Prix d’Abou Dhabi. Son programme d’animation pour fans Yasalam, présenté par e&, est désormais indissociable de la finale du Championnat de Formule 1, et s’impose comme un mélange imbattable de sport d'élite et de divertissement de calibre mondial.

Imagine Dragons, l'un des groupes pop-rock les plus incontournables des classements mondiaux, viendra rejoindre Lewis Capaldi et Zara Larsson, qui donneront le coup d’envoi d’une série de concerts exceptionnels sur l’île de Yas le jeudi 3 décembre. Une affiche prometteuse comprenant de grands noms de la musique mondiale, sera dévoilée prochainement.

Avec une série de hits mondiaux, Imagine Dragons se sont forgé l’un des répertoires les plus reconnaissables de la musique contemporaine, salués à grande échelle pour la force et l’impact de leurs performances live, qui resonnent dans les plus grandes arènes et stades à travers le monde.

David Powell, directeur de la stratégie et du développement commercial chez Ethara, a déclaré : « Imagine Dragons figurent parmi les artistes live les plus marquants de leur génération, avec une popularité qui transcende les publics. Leur talent à livrer des performances de dimension stade, à créer des liens forts avec des fans aux quatre coins du monde, en fait un ajout idéal pour enrichir le programme Yasalam. »

« Le programme Yasalam présenté par e& s'est imposé comme une référence dans le monde du divertissement, accueillant des artistes de premier plan dans la capitale des Émirats arabes unis pour clôturer la saison de Formule 1. Cette nouvelle annonce vient renforcer cette dynamique et témoigne de notre engagement à sublimer l’expérience des fans à l’occasion du rendez-vous phare de l’année. »

Par suite du dénouement historique à trois qui a tenu les fans en haleine jusqu'au dernier tour pour le titre du Grand Prix d'Abu Dhabi 2025, l’anticipation est à son apogée pour ce qui pourrait être une nouvelle course décisive à fort enjeu à Abou Dhabi cette saison. Avec d’autres artistes encore à dévoiler, le Grand Prix d’Abou Dhabi 2026 s’annonce comme un rendez-vous de divertissement immanquable.

L’édition 2026 marquera la 18ème édition du Grand Prix, et se déroulera du 3 au 6 décembre 2026. Les billets sont dès à présent disponibles sur abudhabigp.com, avec un large choix de billets admission générale et tribunes, ainsi que des expériences d’hospitalité premium.

À propos du Grand Prix de Formule 1 Etihad Airways d'Abou Dhabi :

Événement incontournable du calendrier de la Formule 1 depuis son lancement en 2009, le Grand Prix de Formule 1® Etihad Airways d'Abou Dhabi s’impose comme une fin de saison spectaculaire et visuellement époustouflante de la saison du Championnat du monde de F1. L’événement esr reconnu pour son format unique mêlant course de jour et de nuit, ainsi que pour son programme de divertissement emblématique Yasalam, proposant quatre soirées de concerts After-Race (d'après-course) et des after-parties officielles sur l’île de Yas.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Permalink

https://www.aetoswire.com/fr/news/2205202655248

Contacts

Katya Kuftinova

Media@ethara.com

AHS Properties: À 26 ans, Abbas Sajwani investit des milliards dans l'avenir de Dubaï

 

 Dubaï, Émirats arabes unis - jeudi, 21. mai 2026

Désigné plus jeune milliardaire de l'immobilier au monde par Forbes, le fondateur d'AHS Properties développe un portefeuille de projets de 50 milliards de dirhams (AED) avec une conviction inébranlable : Dubaï n'est plus un marché du luxe, mais une destination de choix pour les capitaux.

 

Alors que les capitaux immobiliers mondiaux se réorientent, Abbas Sajwani accélère sa croissance.

Le fondateur et PDG d'AHS Properties, âgé de 26 ans et récemment reconnu par Forbes comme le plus jeune milliardaire arabe et le plus jeune milliardaire mondial de l'immobilier, avec une fortune de 1,9 milliard de dollars, construit l'une des plateformes de développement les plus dynamiques de Dubaï.

Depuis son lancement en 2021, AHS Properties a étendu ses activités, passant de la rénovation de villas de grand luxe à un portefeuille de plusieurs milliards de dollars comprenant des résidences en bord de mer, des immeubles commerciaux de catégorie A et des projets à usage mixte de grande envergure, situés le long des axes stratégiques les plus importants de Dubaï.

Son fleuron commercial, la tour AHS sur Sheikh Zayed Road, a été entièrement vendue pendant sa construction, tandis que son portefeuille de projets devrait atteindre 50 milliards de dirhams d'ici la fin de l'année.

Cette croissance repose sur une stratégie à contre-courant de la prudence générale du marché.

« Le véritable risque sur ce marché n'est pas la volatilité, mais l'attente », a déclaré Sajwani. « Lorsque la conviction devient évidente, l'opportunité est déjà intégrée aux cours. »

Alors que certains segments du capital mondial se sont mis en retrait face à l'incertitude géopolitique et macroéconomique, AHS Properties a poursuivi son déploiement, en réalisant des acquisitions foncières stratégiques et en lançant de nouveaux projets répondant à la demande à long terme.

La thèse de Sajwani est structurelle, et non conjoncturelle.

Il estime que Dubaï est en pleine mutation, passant d'une destination de luxe discrétionnaire à un pôle d'attraction majeur pour les capitaux mondiaux, grâce à l'afflux constant de particuliers fortunés, de fondateurs et de family offices.

« Il ne s'agit pas d'une question de demande à court terme », a-t-il affirmé. « Il s'agit de savoir où les capitaux choisissent d'investir. »

 

Cette perspective est nourrie par une expérience précoce sur les marchés financiers. Ayant débuté en bourse à 14 ans, Sajwani a développé une approche rigoureuse et à long terme de l'allocation de capital, désormais appliquée à grande échelle dans l'immobilier.

Alors que les investisseurs internationaux réévaluent leur exposition géographique, AHS Properties s'impose comme un opérateur convaincu, anticipant les tendances du marché.

 

Pour plus d'informations, veuillez consulter le site web : https://ahsproperties.com/abbas-sajwani/

À propos d’AHS Properties : https://ahsproperties.com/


Permalink
https://www.aetoswire.com/fr/news/2105202655218

Contacts
Tammy Atlee, Directrice de la communication : tammy.atlee@ahs-properties.com

Sura Hammadin, Responsable des relations publiques : sura.hammadin@ahs-properties.com

Lilas Alarbed, Responsable de la communication : lilas.alarbed@ahs-properties.com

فرقة "Imagine Dragons" الموسيقية تنضم إلى حفلات ما بعد سباق جائزة الاتحاد للطيران الكبرى للفورمولا 1 في أبوظبي

  

ستحيي فرقة "Imagine Dragons" العالمية حفلاً رئيسياً في الاتحاد بارك يوم السبت 5 ديسمبر ضمن فعاليات ختام موسم سباقات الفورمولا 1.

أعلنت شركة إثارة، المنظّم لسباق جائزة الاتحاد للطيران الكبرى للفورمولا 1 في أبوظبي، أن إحدى أشهر الفرق الموسيقية العالمية "Imagine Dragons" ستحيي حفل السبت ضمن حفلات ما بعد السباق في ختام موسم الفورمولا 1.

يشكّل هذا الإعلان لحظة بارزة لسباق جائزة أبوظبي الكبرى، حيث أصبحت التجارب الترفيهية الجماهيرية المشوّقة ضمن ياسلام المقدّمة من e& جزءاً لا يتجزأ من أجواء ختام بطولة الفورمولا 1.

وتنضم الفرقة العالمية إلى نجوم الموسيقى العالميين لويس كابالدي و زارا لارسون في إحياء حفلات البرنامج الترفيهي، حيث تبدأ سلسلة العروض في جزيرة ياس يوم الخميس 3 ديسمبر. والإعلان عن المزيد من الفنانين العالميين البارزين قادم لاحقاً.

واكتسبت فرقة "Imagine Dragons" شهرة عالمية كبيرة بفضل أغانيها الناجحة، وحازت على إشادة جماهيرية كبيرة لعروضها الحية القوية بحضور أعداد ضخمة من الجماهير في صالات وملاعب حول العالم.

وقال ديفيد باول، الرئيس التنفيذي للاستراتيجية وتطوير الأعمال في شركة إثارة: "تعد فرقة "Imagine Dragons" واحدة من أبرز الفرق الموسيقية في هذا الجيل، لما تتمتع به من جماهيرية واسعة وقدرة استثنائية على تقديم عروض ضخمة تستقطب الجماهير من حول العالم، ما يعزز أهمية مشاركتها في برنامج ياسلام الترفيهي".

وأضاف: "رسّخت حفلات ياسلام برعاية &e مكانتها في استقطاب أكبر الفنانين العالميين إلى أبوظبي ويشكل هذا الإعلان خطوة بارزة نواصل من خلالها الارتقاء بتجارب الجمهور ضمن أضخم حدث في العام."

وبعد المواجهة التاريخية الثلاثية على لقب البطولة في عام 2025، يتزايد الترقب لما قد يكون سباقاً حاسماً آخر على اللقب في أبوظبي هذا العام. كما يبدو أن سباق جائزة أبوظبي الكبرى 2026 سيكون حدثاً ترفيهياً لا يُفوّت. سيتم الإعلان عن المزيد من حفلات ما بعد السباق وحفلات ياسلام أفتر بارتي الرسمية خلال الأسابيع المقبلة.

وتُقام النسخة الثامنة عشرة من جائزة الاتحاد للطيران الكبرى للفورمولا 1 في أبوظبي خلال الفترة من 3 ديسمبر إلى 6 ديسمبر 2026. وتتوفر التذاكر عبر الموقع الإلكتروني abudhabigp.com.

نبذة عن جائزة أبوظبي الكبرى للفورمولا 1

منذ انطلاقها على حلبة مرسى ياس يوم 30 أكتوبر 2009، حافظت جائزة الاتحاد للطيران الكبرى للفورمولا 1 في أبوظبي على مكانتها البارزة ضمن أجندة الفورمولا 1، واعتمدت كختام رسمي للموسم منذ عام 2014. وتُعرف عالمياً بصيغة سباقها الفريدة بين النهار والليل، والتجارب الترفيهية الجماهيرية المشوّقة ضمن حفلات ياسلام .

abudhabigp.com

الرابط الثابت

https://www.aetoswire.com/ar/news/2105202655231

جهات الاتصال

كاتيا كوفتينوفا

Media@ethara.com

AHS Properties: At 26, Abbas Sajwani Is Deploying Billions Into Dubai’s Future

 

 Dubai, United Arab Emirates - Thursday, 21. May 2026

Named the youngest billionaire in real estate globally by Forbes, the AHS Properties founder is scaling a AED 50 billion pipeline on a single conviction: Dubai is no longer a luxury market - it’s a capital destination.

 

While global real estate capital recalibrates, Abbas Sajwani is accelerating.

The 26-year-old Founder and CEO of AHS Properties - recently recognised by Forbes as the youngest Arab billionaire and the youngest billionaire globally in real estate, with a net worth of $1.9 billion - is building one of the fastest-scaling development platforms in Dubai.

Since launching in 2021, AHS Properties has expanded from ultra-luxury villa redevelopments into a multi-billion-dollar portfolio spanning waterfront residential, Grade-A commercial, and large-scale mixed-use developments across Dubai’s most strategic corridors.

Its commercial flagship, AHS Tower on Sheikh Zayed Road, sold out during construction, while its broader pipeline is projected to reach AED 50 billion by year-end.

This growth is underpinned by a strategy that runs counter to broader market caution.

“The real risk in this market isn’t volatility, it’s waiting,” Sajwani said. “By the time conviction feels obvious, the opportunity is already priced in.”

At a time when segments of global capital have moved to the sidelines amid geopolitical and macroeconomic uncertainty, AHS Properties has continued to deploy, advancing strategic land acquisitions and launching new developments aligned with long-term demand.

Sajwani’s thesis is structural, not cyclical.

He believes Dubai is undergoing a permanent repositioning, from a discretionary luxury destination to a core hub for global capital, driven by sustained inflows of ultra-high-net-worth individuals, founders, and family offices.

“This isn’t about short-term demand,” he said. “It’s about where capital is choosing to live.”

That perspective is informed by early experience in financial markets. Beginning equity trading at 14, Sajwani developed a disciplined, long-term approach to capital allocation, one now applied at scale across real estate.

As global investors reassess geographic exposure, AHS Properties is emerging as a high-conviction operator, building not around market sentiment, but ahead of it.

For further media information visit: https://ahsproperties.com/abbas-sajwani/

About AHS Properties, please visit: https://ahsproperties.com/


Permalink
https://www.aetoswire.com/en/news/1905202655157

Contacts
Tammy Atlee, Communications Director: tammy.atlee@ahs-properties.com

Sura Hammadin, PR Manager: sura.hammadin@ahs-properties.com

Lilas Alarbed, Communications Manager: lilas.alarbed@ahs-properties.com

 

MetLife وGlobal Citizen تطلقان تحدي وسائل التواصل الاجتماعي "Footwork for Futures" للمساعدة في توسيع نطاق الوصول إلى التعليم والرياضة

 نيويورك - الاثنين, 18. مايو 2026 أيتوس واير طباعة 

 ستدعم جميع التبرعات صندوق FIFA Global Citizen Education Fund، استكمالاً لالتزام مؤسسة MetLife بمبلغ 9 ملايين دولار

(BUSINESS WIRE)-- أعلنت MetLife وGlobal Citizen اليوم عن إطلاق Footwork for Futures، وهو تحدٍ عالمي على وسائل التواصل الاجتماعي بطابع كرة القدم، يدعم وصول الأطفال إلى التعليم والرياضة عاليي الجودة لتعزيز بناء مجتمعات أكثر ثقة ومرونة.

 يدعو تحدي Footwork for Futures الأفراد لمشاركة مقطع فيديو قصير لأنفسهم وهم يستعرضون مهارات تنطيط كرة القدم –أو يحاولون تنطيطها– على منصات Instagram أو LinkedIn أو X أو TikTok أو Facebook مع تضمين الوسم #FootworkForFutures، أو من خلال تقديم مقطع فيديو عبر تطبيق Global Citizen. مقابل كل فيديو مؤهل يتم تقديمه، ستتبرع شركة MetLife بمبلغ 5 دولارات لصندوق FIFA Global Citizen Education Fund، بحد أقصى 100,000 دولار، للمساعدة في دعم حصول الأطفال على تعليم ورياضة عالية الجودة من خلال منح للمنظمات المجتمعية في جميع أنحاء العالم.

وتأتي هذه الحملة الاجتماعية استكمالاً لمساهمة مؤسسة MetLife Foundation بمبلغ 9 ملايين دولار بصفتها من المؤسسين لصندوق FIFA Global Citizen Education Fund. يقدم الصندوق منحًا للمنظمات في المجتمعات حول العالم التي تقدم برامج تعليمية ورياضية. وتستغل مبادرة Footwork for Futures حماس بطولة كأس العالم FIFA 2026™ هذا الصيف لمساعدة المنظمات على تطوير مبادراتها، بهدف تعزيز ثقة الأطفال بأنفسهم وتقوية المجتمعات.

قالت Nuria Garcia، رئيسة الاستدامة العالمية في MetLife ورئيسة MetLife Foundation: "إن صندوق FIFA Global Citizen Education Fund دليلٌ على ما يمكن تحقيقه عندما نجمع بين حب العالم لكرة القدم وقوة التعليم لتعزيز مجتمعاتنا". "يساعد تحدي Footwork for Futures على جعل هذه المهمة ممتعة وحقيقية ومتاحة للجميع. كل فيديو يتم تقديمه هو خطوة ذات مغزى نحو بناء مستقبل أكثر ثقة للشباب في جميع أنحاء العالم".

المشاركة في Footwork for Futures مفتوحة لجميع الأفراد، بغض النظر عن المهارة أو القدرة أو الخبرة، مما يتيح لكل شخص استعراض أسلوبه الخاص في إبقاء كرة القدم متحركة. تستمر المبادرة من 12 مايو إلى 19 يوليو 2026، أو حتى تصل التبرعات إلى 100,000 دولار. تُشارَك المشاركات المستلَمة بعد هذه الفترة؛ ومع ذلك، لن تسهم في تقديم تبرعاتٍ إضافيةٍ. يتم تشجيع المشاركين، ولكن ليس مطلوبًا، على ترشيح الأصدقاء والعائلة للانضمام إليهم.

 يجب أن تتبع جميع مقاطع الفيديو قواعد منصات وسائل التواصل الاجتماعي المعنية وشروط وأحكام الحملة. لكي يكون مقطع الفيديو مؤهلاً، يجب أن يظهر فيه بوضوح شخص حقيقي يستعرض مهارات تنطيط كرة القدم (أو يحاول تنطيطها) بأمان ومسؤولية. تحتفظ Global Citizen بالحق في استبعاد أي مشاركة لا تفي بهذه المعايير. لمزيد من المعلومات حول كيفية المشاركة، تفضل بزيارة: Footwork for Futures.

 حول MetLife

.MetLife, Inc (المدرجة في بورصة نيويورك تحت الرمز: MET)، من خلال شركاتها التابعة والمنتسبة (يشار إليها هنا باسم "MetLife")، هي واحدة من الشركات الرائدة عالميًا في مجال الخدمات المالية، حيث تقدم خدمات التأمين والمعاشات التقاعدية ومزايا الموظفين وإدارة الأصول لمساعدة العملاء الأفراد والمؤسسات على بناء مستقبل أكثر ثقة. تأسست شركة MetLife في عام 1868، ولها عمليات في أكثر من 40 سوقًا على مستوى العالم، وتحتل مراكز رائدة في الولايات المتحدة وآسيا وأمريكا اللاتينية وأوروبا والشرق الأوسط. لمزيد من المعلومات، يرجى زيارة www.metlife.com.

 حول MetLife Foundation

 في MetLife Foundation، نحن ملتزمون بقيادة الحراك الاقتصادي الشامل. نتعاون مع المنظمات غير الربحية ونقدم منحًا تتماشى مع ثلاثة مجالات تركيز استراتيجية –التمكين الاقتصادي والصحة المالية والمجتمعات المرنة– مع إشراك متطوعي موظفي MetLife للمساعدة في إحداث تأثير. تأسست MetLife Foundation في عام 1976، وعلى مدار 50 عامًا واصلت تقليد MetLife الطويل في المشاركة المجتمعية والتفاعل. ساهمت MetLife Foundation منذ إنشائها بأكثر من مليار دولار لتعزيز المجتمعات التي تتواجد فيها MetLife. لمعرفة المزيد عن MetLife Foundation، تفضل بزيارة www.metlife.org.

 حول Global Citizen

 Global Citizenهو أكبر حركة في العالم لإنهاء الفقر المدقع. هذه الحركة مدعومة بمجتمع عالمي من المناصرين اليوميين الذين يرفعون أصواتهم ويتخذون خطوات فعلية، ويجري تعزيزها من خلال الحملات والفعاليات التي تجمع القادة في مجالات الموسيقى، والترفيه، والسياسة العامة، والإعلام، والعمل الخيري، والقطاع الخاص. ومنذ انطلاقها، تم تخصيص أكثر من 50 مليار دولار من الالتزامات المعلنة على منصات "Global Citizen"، مما أثر إيجابًا على حياة 1.3 مليار شخص. تأسست Global Citizen في أستراليا في عام 2008، وتعمل في الولايات المتحدة والمملكة المتحدة وفرنسا وألمانيا وإسبانيا وسويسرا والبرازيل وكندا وأستراليا وجنوب إفريقيا ونيجيريا وغانا ورواندا والإمارات العربية المتحدة وعبر آسيا. انضم إلى الحركة على globalcitizen.org، وقم بتنزيل تطبيق Global Citizen، وتابع Global Citizen على TikTok وInstagram وYouTube وFacebook وX وLinkedIn.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260511913741/en

الرابط الثابت

https://www.aetoswire.com/ar/news/1805202655130

جهات الاتصال

 وسائل الإعلام

 MetLife:

  Peggy Fries Carlton

 peggy.f.carlton@metlife.com

Global Citizen:

  media@globalcitizen.org

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis

 SAN MATEO, Calif. - Thursday, 21. May 2026 AETOSWire

Randomized controlled trial will evaluate both symptom progression and underlying biology

(BUSINESS WIRE) -- Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness.

Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pre-symptomatic stage offering a window for preventive treatment. However, while diagnostic tools for detecting CHR-P are well-developed, treatment options remain limited. Currently, there is no specific, indicated treatment to reduce the rate of transition to full psychosis in CHR-P patients, underlining an urgent need for developing novel interventions.

This randomized controlled trial (RCT) will assign 50 CHR-P patients (aged 14-35) to either a 12-week modified ketogenic diet or a control diet. Symptom severity will be monitored throughout the trial using the Comprehensive Assessment of At-Risk Mental States (CAARMS) assessment tool, designed specifically to assess symptom severity in young people at high risk of developing psychosis. Participants will receive support from a registered dietitian and will use glucose/ketone meter kits to track adherence to the ketogenic diet. To evaluate efficacy and tolerability, the research team will assess symptom severity, cognitive function, sleep behavior, and physical health. The trial will also follow patients’ health status for up to three years after the intervention via electronic health records to evaluate the longer-term impact.

“We see promise in ketogenic therapy as a non-stigmatizing, accessible intervention for those navigating early signs of psychosis. If effective, the diet could represent a novel tool that will allow us to intervene before psychotic onset,” said study lead Amedeo Minichino, MD DPhil CCT, Associate Professor, Honorary Consultant Psychiatrist, and Wellcome Trust Early Career Fellow at the University of Oxford. “We are hopeful that by studying the critical window that often precedes psychotic onset, we can change the long-term trajectory of mental well-being in our patients."

Since the majority of CHR-P patients do not receive antipsychotics, this will offer a unique opportunity to evaluate the clinical outcomes of ketogenic therapy as a stand-alone treatment, as well as to explore the biological mechanisms underlying both the disease and the intervention. New and growing evidence suggests that impaired brain energy metabolism, including mitochondrial dysfunction, may help us identify individuals with CHR-P who are more likely to later develop psychosis. In a subgroup of patients, the trial will measure brain energy directly using blood biomarkers and neuroimaging.

“This study is an important step forward in understanding the potential of ketogenic therapy on physical and mental health in this highly vulnerable patient group,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group. “This ambitious project represents a rare opportunity to gain a deeper understanding of how ketogenic therapy could fundamentally transform the trajectory of serious mental illness in a largely medication-naive population. We are thrilled to support the research team at Oxford in this first-of-its-kind trial.”

To learn more about Baszucki Group’s ongoing funded studies, visit the Metabolic Mind website.

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages grantmaking, impact investing, advocacy, storytelling, and community building to drive foundational change in science, medicine, farming, food, and environmental ecosystems. A primary focus of Baszucki Group is supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience with the goal of improving mental health outcomes. To learn more about metabolic approaches to mental disorders and brain health, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521877110/en/

Permalink

https://www.aetoswire.com/en/news/2105202655224

Contacts

Baszucki Group media contact: media@baszuckigroup.org

 

Meeting Between Senior Delegations of the Central Bank of Libya and Numisma Bank

 

 (BUSINESS WIRE) -- A delegation from Numisma Bank led by the bank’s Chairman and Chief Executive Officer and comprised of senior Compliance and Operations officials met with H.E. Naji Mohammed Issa, Governor of the Central Bank of Libya (“CBL”), and senior CBL officials in Tripoli.

The two teams held high-level discussions on the historic structural reforms being implemented by H.E. Naji Mohammed Issa, and the rising confidence across various sectors of the international financial markets.

The team also held detailed discussions on compliance and risk controls that are being implemented by the Central Bank of Libya across the Libyan banking sector that are modeled per international banking standards.

Numisma Bank’s Chairman and CEO praised the Governor’s reforms, saying, “The structural changes being implemented by the Central Bank across Libyan commercial banks, especially as related to foreign exchange and US Dollars, are being noted by the international community. Clear evidence of the success of these changes lies in the stabilization of the Libyan Dinar’s exchange rate versus leading foreign currencies. Central Bank of Libya’s programs will also help significantly reduce the incidence of counterfeit currency across the Libyan market when sourced from official channels per Central Bank of Libya‘s guidelines.”

In May 2026, the Central Bank of Libya commenced the distribution of U.S. Dollars through commercial banks, providing a sustainable, internationally compliant, institutional-grade supply chain to underpin the distribution of US Dollars and other currencies at scale. These actions have had a stabilizing effect on Libyan foreign exchange rates and have broadly been noted across global financial markets.

The Central Bank and Numisma Bank’s teams agreed to continue their ongoing dialogue and cooperation over the long-term in support of the Central Bank of Libya‘s foreign exchange markets-related initiatives.

About the Central Bank of Libya

The Central Bank of Libya (CBL) is Libya’s monetary authority, responsible for currency stability, banking sector regulation, and foreign exchange management. Under H.E. Governor Naji Mohammed Issa, the CBL has undertaken a significant program of institutional reform, including the modernization of compliance controls, the introduction of formal regulatory oversight of currency exchange activities, and the restoration of a unified, internationally recognized central banking institution for Libya.

About Numisma Bank

Numisma Bank is a U.S. based, chartered and regulated bank, and a leading provider of fully insured, regulatorily compliant currency solutions to Central Banks and Commercial Banks worldwide.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521351546/en/

Permalink

https://aetoswire.com/en/news/2105202655229

Contacts

MEDIA CONTACT

Numisma Bank | Greenwich, Connecticut, United States

contact@numismabank.com

 

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

  

Department of Health – Abu Dhabi standardizes operating rooms on Polyphonic™ to empower clinicians and advance global AI

Building on collaboration with AWS and NVIDIA, the effort expands the ecosystem of healthcare and technology leaders scaling surgical innovation

(BUSINESS WIRE) -- Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience.

Integrating Johnson & Johnson’s Polyphonic™ open digital ecosystem with the Department of Health – Abu Dhabi and technology partners including Amazon Web Services (AWS) and NVIDIA, the initiative is expected to deploy the Polyphonic Surgery application into Abu Dhabi’s intelligent health system to connect operating rooms across the emirate to a surgical intelligence system. Through Polyphonic, relevant procedures contribute high-fidelity video and multimodal data that will be curated, labeled, and continuously flow into a governed infrastructure. Designed to accelerate responsible and trusted AI and compress technology development, the ecosystem will connect insights generated before, during, and after surgery.

The initiative aligns with Johnson & Johnson’s work to shape the future of surgery across open, laparoscopic, and robotic surgery, bringing together deep surgical expertise with the open ecosystem architecture the next era demands.

“Today marks an important step forward for the global community to advance innovation for surgical teams and in service of patients,” said Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson. “No single company, hospital, or developer can do this alone. We must bring together innovative health systems, technology leaders, clinicians and researchers with a drive to start now and serve the world.”

From Abu Dhabi to Global Surgical AI

Deploying the Polyphonic network at scale across Abu Dhabi supports a first-of-its-kind surgical network in the emirate. Cleveland Clinic Abu Dhabi, PureHealth, Mediclinic Group, and NMC Healthcare will deploy Polyphonic across operating rooms. Participating hospitals will use the Polyphonic Surgery solution, capturing surgical video, enabling real-time collaboration, and supporting structured case review, peer consultation, and case efficiency. As teams integrate these tools into routine care, each case will add to a structured, anonymized surgical dataset that will establish an approved source for AI development in surgical care — beginning in Abu Dhabi and in the future extending globally.

This builds on Abu Dhabi’s rapidly advancing intelligent health system of AI-enabled infrastructure, assembling the conditions for AI to scale in surgery: a coordinated network of hospitals, government institutions, academic partners, research organizations, and technology leaders, working within a single foundation where data can be responsibly aggregated, models validated, and improvements scaled from one operating room to many.

“This program builds on Abu Dhabi’s intelligent health system, where clinical care, data, AI and research are connected to deliver impact at scale,” H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said. “By extending the intelligent OR network across hospitals, we are standardizing capabilities, enabling shared intelligence, and creating a continuous learning system where every procedure has the potential to improve the next. Moving from individual advancements to system-wide progress for patients globally.”

“Working with the Department of Health – Abu Dhabi and their integrated health ecosystem has helped us to accelerate the pathway of building the first node of a global surgical network,” said Shan Jegatheeswaran, Global President, Polyphonic, MedTech, Johnson & Johnson. “We are already seeing that same spirit in other health authorities, hospital leaders, academic institutions, and technology partners joining this ecosystem. Our role is to create the conditions for the leading minds in medicine, technology, and research to do their best work together in service of better outcomes for patients, everywhere.”

About Polyphonic™

Polyphonic™ is Johnson & Johnson MedTech’s open ecosystem, created to harness the power of digital technology, activate AI-driven innovation, and connect surgical minds worldwide. Polyphonic Surgery empowers surgeons and multidisciplinary teams to leverage video and telepresence for collective review, peer assessment, and streamlined information in one convenient platform. Beneath these solutions sits a governed data platform creating the foundation designed for the development of next generation surgical AI. Built to work across surgical environments, Polyphonic is designed to grow through native development, technology partnerships, and collaborations with innovators shaping the future of surgery.

Surgical Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what’s next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to Polyphonic. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521559549/en/

Permalink

https://aetoswire.com/en/news/2105202655225

Contacts

Media:

Lindsey Diaz-MacInnis

ldiazmac@its.jnj.com

 

Imagine Dragons to Perform at Abu Dhabi Grand Prix

  

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi.

The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally.

The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed.    

With their popular top hits, Imagine Dragons have built one of contemporary music’s most recognisable catalogues, earning widespread acclaim for powerful live performances that have filled arenas and stadiums worldwide.

David Powell, Chief Portfolio & Strategy Officer at Ethara, said: “Imagine Dragons are one of the defining live acts of this generation, with mass appeal to all. Their ability to deliver stadium-scale performances that connect with audiences around the world makes them the perfect addition to the Yasalam program.

“Yasalam presented by e& has become synonymous with bringing the biggest artists in the world to Abu Dhabi, and this announcement is another major statement as we continue to elevate the fan experiences at the biggest event of the year.”

Following the historic three-way championship showdown in 2025, the anticipation is building for what could be another high-stakes title-deciding race in Abu Dhabi this year.  With more artists to be announced soon the 2026 Abu Dhabi Grand Prix is shaping up to be an unmissable entertainment spectacle.

This year's event will be the 18th edition of the event, taking place on 3-6 December 2026 with tickets available across General Admission, Grandstands and Hospitality at abudhabigp.com

ABOUT THE FORMULA 1 ABU DHABI GRAND PRIX

A standout fixture on the Formula 1 calendar since the inaugural event in 2009, the Formula 1® Etihad Airways Abu Dhabi Grand Prix is the season finale of the F1 World Championship The event is renowned for its unique day-night format and signature entertainment programme Yasalam featuring four nights of After-Race Concerts and official After-Parties on Yas Island.

Permalink

https://www.aetoswire.com/en/news/2105202655230

Contacts

Katya Kuftinova

Media@ethara.com

Variational Secures ~$50M to Bring Liquidity from Traditional Markets To Crypto

GEORGE TOWN, Cayman Islands - Thursday, 21. May 2026 AETOSWire 

Already powering $200B+ in crypto volume, Variational is using its zero-fee liquidity aggregation model to bring traditional markets on-chain.

(BUSINESS WIRE) -- Variational, a protocol for on-chain derivatives trading, has announced a ~$50M Series A raise led by Dragonfly with support from Bain Capital Crypto, Coinbase Ventures, and other strategic investors. The funding coincides with the launch of the protocol’s first Real-World Asset (RWA) markets. This initial rollout allows traders to access perpetuals on select commodities alongside their crypto portfolio, laying the groundwork for Variational to route liquidity directly from traditional markets in the coming months.

While the broader crypto industry is attempting to bootstrap RWA liquidity from scratch on isolated Central Limit Order Books (CLOBs), Variational introduces a fundamentally different architecture. Instead of starting new order books from scratch for each new market, Variational aggregates and routes liquidity from both existing traditional and on-chain markets.

By solving this "cold start" problem, Variational will allow traders to access a massive menu of global assets, from indices and single-name stocks to FX and crypto, all from a single account.

In January 2025, Variational was released into an invite-only private beta. Since then, the trading platform has processed $200+ billion in trading volume across 50k+ accounts, accumulated over $750 million in open interest, and shared over $7 million in rewards with traders.

“You can't rebuild forty years of traditional market depth from scratch on a crypto order book,” said Lucas Schuermann, CEO of Variational. “Traditional finance solved this problem with the brokerage model--we're bringing that model on-chain, aggregating RWA liquidity from where it already exists rather than waiting for it to migrate.”

Variational’s initial “Phase 1” RWA release includes gold, silver, copper, and WTI Crude. This initial rollout is intended to stress-test the protocol's cross-margin engine and on-chain settlement using aggregated crypto-native liquidity. Once the infrastructure is validated, “Phase 2” will begin routing liquidity directly from TradFi sources, aiming to bring over 100+ new markets on-chain this summer.

"Order books are fine when you have the liquidity to anchor them. But for the massive universe of RWAs, more often it’s a mistake. Everyone else is trying to suck liquidity through a straw, spending millions on incentives just to end up with thin books and volatile pricing,” said Haseeb Qureshi, Managing Partner at Dragonfly. “Variational's model sidesteps that entirely, mainlining liquidity from traditional markets directly on-chain. It's what 'perps on everything' requires to work at scale."

Variational’s roadmap for 2026 includes listing more RWA markets, further deepening RWA liquidity with additional partnerships, and releasing a trading API. Progress can be followed on Variational’s X Account.

About Variational

Variational is a peer-to-peer trading protocol for perpetuals and generalized derivatives that has processed $200B+ in trading volume. Variational powers Omni, a zero-fee trading platform that aggregates liquidity from both on-chain and traditional markets.

Variational is built by a veteran team with decades of experience from firms like Google, Meta, Virtu, IMC, and Jane Street, and backed by leading investors including Dragonfly, Bain Capital Crypto, and Coinbase Ventures.

For more information, visit https://variational.io.

About Dragonfly

Dragonfly is a $4B crypto-focused global investment firm. Since 2017, Dragonfly has been at the forefront of blockchain and crypto innovation with a long-term oriented, technical, and research-driven approach, having been early backers of some of the most influential protocols and companies in the industry.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520402312/en/

Permalink

https://www.aetoswire.com/en/news/2105202655202

Contacts

Media Contact

Max Bibeau

press@variational.io

Marquee Brands Enters Strategic Partnership With DAMAC Group for a Majority Interest in Roberto Cavalli

 

The Partnership Positions Roberto Cavalli for a New Phase of Global Expansion and Omnichannel Growth

(BUSINESS WIRE) -- Marquee Brands, the premier global brand management company and leading brand accelerator, today announced a definitive agreement for a majority interest in Roberto Cavalli, through a strategic partnership with DAMAC Group, the leading Dubai-based global conglomerate and luxury real estate developer. The transaction is expected to close in the second quarter of 2026, after which DAMAC Group will remain a significant shareholder. Founded in Florence in 1970, Roberto Cavalli the iconic luxury house celebrated for its avant-garde design and distinct Italian craftsmanship joins Marquee Brands’ portfolio of timeless global brands, including Martha Stewart, Laura Ashley, Sur La Table, BCBGMAXAZRIA and Stance. The addition of Roberto Cavalli further strengthens Marquee Brands’ position as a leader in the luxury and lifestyle sectors, bringing total portfolio-wide retail sales to approximately US$5 billion.

“Roberto Cavalli stands as one of luxury’s defining Italian houses, with a bold creative identity and enduring brand ethos,” said Heath Golden, CEO, Marquee Brands. “We see extraordinary potential to build on that foundation through thoughtful brand stewardship and strategic expansion. In partnership with DAMAC, a leader in luxury real estate, we will continue to elevate the Roberto Cavalli experience worldwide.”

Hussain Sajwani, Founder of DAMAC Group, said: “Roberto Cavalli is one of the most distinctive luxury brands in the world. After several years of solidifying the brand’s foundation, we set out to find a strategic partner with the skillset to take the brand to the next level. We are confident Marquee Brands is the right partner to do so. Given our love for the brand and meaningful ongoing shareholdings, we look forward to supporting Marquee Brands’ efforts, by among other things, continuing to expand the Roberto Cavalli lifestyle through branded residences and hospitality projects in premier global destinations, an area that remains fully owned and operated by DAMAC. This collaboration marks an exciting new era for the brand. We look forward to its significant future expansion.”

Marquee Brands, owned by funds managed by Neuberger, a global investment management firm, continues to scale its global platform by acquiring heritage brands with deep consumer resonance. Roberto Cavalli marks the twenty-second brand in Marquee Brands’ portfolio.

“Marquee Brands has established a proven, capital‑efficient business model for driving growth through disciplined brand management, strategic partnerships and a long-term investment horizon,” said Zachary Sigel, Managing Director at Neuberger and Co-Founder of Marquee Brands. “The acquisition of Roberto Cavalli reinforces Neuberger’s confidence in the platform and its ability to continue to create value for investors.”

The partnership between Marquee Brands and DAMAC expands the global reach of the Roberto Cavalli brand, bringing together their complementary strengths and shared commitment to elevating the legendary Italian maison. Marquee Brands will accelerate Roberto Cavalli’s growth by introducing new categories, services and experiential touchpoints across Europe, the United Kingdom, the United States, the Middle East, Asia Pacific and Latin America.

DAMAC will continue to scale the brand’s presence through Roberto Cavalli-branded residences and hospitality projects across key global markets, reinforcing the brand’s luxury position and desirability. The partnership creates a powerful platform that unites Marquee Brands’ expertise in global brand development with DAMAC’s leadership in luxury real estate and hospitality, unlocking significant new opportunities for the future of Roberto Cavalli.

As part of the transaction, Marquee Brands announces Milan-based partner The Level Group (TLG) as its core operating partner. TLG will lead the development, manufacturing and distribution of the brand’s women’s and men’s collections, ensuring a unified and elevated product vision across key markets. In addition, TLG will assume responsibility for retail and e‑commerce operations and wholesale distribution in Europe and the United States, strengthening Roberto Cavalli’s direct-to-consumer presence and global retail strategy.

RBC Capital Markets served as financial advisor and Greenberg Traurig acted as legal advisor to Marquee Brands. BDA Partners served as financial advisor to DAMAC Properties.

ABOUT ROBERTO CAVALLI

Founded in 1970, Roberto Cavalli is a leading Italian brand in fashion, accessories and luxury lifestyle. Defined by a glamorous contemporary aesthetic, the brand is the quintessential expression of Italian excellence, craftsmanship and its Mediterranean origins. The Roberto Cavalli portfolio is positioned within the luxury segment and includes the Home, Junior, Eyewear, Perfumes, Watches and Just Cavalli collections. www.robertocavalli.com

ABOUT MARQUEE BRANDS

Marquee Brands is the premier accelerator of timeless brands, unlocking value and building global influence. With a focus on driving growth and building sustainable brand equity, we partner with best-in-class manufacturers, operators, retailers, and distributors to scale brands across markets and channels. Marquee Brands’ global portfolio spans three distinct platforms: Home & Culinary, Fashion & Lifestyle, Luxury and Active & Outdoor. The portfolio of brands includes Martha Stewart, Laura Ashley, Sur La Table, Emeril Lagasse, America’s Test Kitchen, BCBGMAXAZRIA, BCBG, Ben Sherman, Bruno Magli, Anti Social Social Club, Totes, Isotoner, Destination Maternity, Motherhood, A Pea in the Pod, Stance, Dakine and Body Glove. For more information visit, www.marqueebrands.com.

ABOUT NEUBERGER PRIVATE MARKETS

Neuberger Private Markets is a division of Neuberger and has been an active and successful private markets investor since 1987. Neuberger Private Markets invests across strategies, asset classes, and geographies for a large number of sophisticated and renowned institutions and individuals globally. As of December 31, 2025, Neuberger Private Markets manages over $155 billion of investor commitments across primaries, co-investments, secondaries, private credit, and specialty strategies. Neuberger Private Markets has an experienced and diverse team of over 500 professionals with a global presence in 17 offices globally.

ABOUT DAMAC GROUP

DAMAC Group is a global private business conglomerate founded by Hussain Sajwani in 1982. Starting in catering and logistics, it has expanded into diverse industries, including real estate, hospitality, data centers, fashion, and capital markets. DAMAC Properties is the largest private real estate developer in the UAE and the Middle East, and has been at the forefront of the Middle East’s luxury real estate market since 2002, delivering award-winning residential, commercial and leisure properties across the region and internationally, including in the UAE, Saudi Arabia, Qatar, Jordan, Lebanon, Iraq, the Maldives, Canada, the United States, as well as the United Kingdom. Since then, DAMAC has delivered more than 50,000 homes with over 55,000 more in diverse planning and development phases, joining forces with some of the world’s most eminent fashion and lifestyle brands to create tremendous living experiences, such as Roberto Cavalli and de GRISOGONO. With a consistent vision and momentum, DAMAC is building the next generation of luxury living across the globe. The Group also owns hotel assets under brands such as Radisson, Paramount, and Rotana, with an expanding hospitality portfolio. Beyond real estate, DAMAC is a leader in the data center industry through DAMAC Digital and has acquired luxury brands Roberto Cavalli and de GRISOGONO. Through DAMAC Capital, it invests in future-focused industries like tech, finance, and life sciences. Committed to social impact, the Hussain Sajwani – DAMAC Foundation supports education, innovation, and community-driven initiatives. For more information visit, www.damacgroup.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520070705/en/

Permalink

https://www.aetoswire.com/en/news/2105202655204

Contacts

For media inquiries, contact the Marquee Brands Press Office:

Email: corporate@marqueebrands.com

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall

 

NEW YORK - Thursday, 21. May 2026 AETOSWire Print 

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness

 

(BUSINESS WIRE)--Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall.

The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions.

The Moment Before the Ad Matters

The research challenges long-held assumptions about media value, showing that not all impressions are equal.

Live sports remain one of the last entertainment formats with large-scale audiences. According to Sports Business Journal, sports accounted for 96 of the top 100 most-watched U.S. telecasts of 2025. But scale alone does not make every impression equally valuable. Fans’ attention rises and falls with the action, making the moments immediately after high-intensity plays especially powerful for advertisers. Cutting through requires knowing when those moments occur and being ready to reach the right fans in real time with messaging tailored to the moment.

Key findings include:

Emotional intensity immediately before an ad significantly increases memory encoding and recall

The 60 seconds following a high-impact moment represent the peak window for advertising effectiveness

Emotional context can have a greater influence on recall than the ad creative itself in real time.

A Shift from Buying Media to Activating Moments

The findings point to a fundamental shift in how sports media should be planned and valued. The Live Moment Effect research shows that recall is concentrated around moments of peak emotion. As a result, aligning ad delivery and ad messaging with real-time game context can significantly improve campaign outcomes.

Genius Sports is applying these insights through the Genius Sports Moment Engine, which uses official game data and real-time signals to identify and activate around high-impact moments as they occur. By enabling brands to align campaigns with peak attention windows, the Genius Sports Moment Engine allows advertisers to improve outcomes by optimizing timing rather than increasing volume.

“The sports advertising playbook is being rewritten around the moments when fans are most emotionally engaged,” said Josh Linforth, Chief Revenue Officer at Genius Sports. “Brands should be present across the full fan journey — pre-game, in-game and post-game — because every stage of the sports experience creates an opportunity to connect. Within that always-on presence, this research shows that certain moments carry extra impact. When a momentum shift, near score or decisive play changes how fans are feeling and focusing, the message should change with it. Genius Sports Moment Engine uses official game data and real-time signals to help advertisers identify those high-impact windows as they happen and tailor campaigns accordingly across every screen.”

“Our research continues to reinforce a principle we’ve observed across the media landscape: context matters,” said Phillip Lomax, Chief Revenue Officer at MediaScience. “In live sports, emotionally heightened moments prime audiences differently, changing their cognitive and emotional state before an ad is even delivered. When an advertisement aligns with that moment, the context and the creative converge to strengthen memory encoding and significantly amplify recall. That creates a meaningful opportunity for brands to improve performance through real-time, moment-based activation rather than simply increasing media volume.”

The research analyzed viewer response to advertising across varying levels of emotional intensity during live sports, measuring attention, cognitive engagement, and brand recall in controlled environments. Access the full study here.

About Genius Sports

Genius Sports is the official data, technology and broadcast partner that powers the global sports, betting and media ecosystem. As the operating system of modern sport, our technology is used in over 150 countries worldwide, creating highly immersive products that enrich fan experiences across the entire sports industry.

We are the trusted partner to over 1,000 sports organizations, including many of the world’s largest leagues, teams, sportsbooks, brands and broadcasters, such as the NFL, English Premier League, NCAA, DraftKings, FanDuel, bet365, Coca-Cola, EA Sports, CBS, NBC and ESPN.

Genius Sports is uniquely positioned through AI, computer vision and big data to power the future of sports fan experiences. From delivering augmented broadcasts and enhanced highlights, to automated officiating tools, immersive betting solutions and personalized marketing activations, we connect the entire sports value chain from the rights holder all the way through to the fan.

About MediaScience

MediaScience is the industry leader in media and advertising innovation research, trusted by major networks and platforms including Disney, NBCUniversal, Google and most other national TV networks and social media platforms. The company's work at the intersection of science and creativity continues to redefine how stories are told, measured, and experienced in the modern media landscape.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521475265/en/

Permalink

https://www.aetoswire.com/en/news/2105202655227

Contacts

Tony Marlow

CMO, Genius Sports

tony.marlow@geniussports.com

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

 

SAN CARLOS, Calif. - 

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment

Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline

 

(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm).

Continuing to raise the bar in CLL

At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL.

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:

“Seventy-eight-month follow-up data from SEQUOIA underscore what it truly takes to lead in CLL over the long term: long-term efficacy, ability for sequencing treatments, and confidence in first-line treatment decisions. Building on that leadership, we’re excited to be rapidly advancing the next generation of medicines, including sonrotoclax-based combinations and our BTK degrader BGB-16673, which are designed to extend what is possible for patients across lines of therapy.”

Key data presentations in CLL include:

New results from the SEQUOIA trial with 78 months follow-up reinforce BRUKINSA® (zanubrutinib) as the foundational BTK inhibitor in CLL, with durable disease control that continues to raise expectations for what patients and physicians should expect from first-line therapy over the long term. Data will be presented at both ASCO and EHA.

A subgroup analysis of SEQUOIA, which includes one of the largest and longest-followed cohorts of patients aged ≥80 years ever reported in a Phase 3 CLL study, showing that age did not limit benefit. Data will be presented at EHA 2026.

Oral presentation at EHA 2026 of updated data of BeOne’s foundational BTK degrader – BGB-16673 – in patients with R/R CLL, demonstrating promising and durable activity and a manageable safety profile. An additional poster will be shared featuring never-before-presented data of BGB-16673 in BTK-naïve patients. BGB-16673 is the most advanced BTK degrader in the clinic, with more than 1,100 patients dosed.

Data from the all-oral combination of BeOne’s foundational BCL2 inhibitor sonrotoclax plus zanubrutinib (ZS) in CLL, which demonstrated deep responses, unprecedented speed to undetectable MRD, and durable remissions and a generally well-tolerated safety profile. These data reinforce the potential for a next-generation, time-limited approach designed to deliver long-term outcomes without compromising durability or safety. Data will be presented as a poster at ASCO 2026 and an oral presentation at EHA 2026.

Accelerating a high-potential solid tumor portfolio

BeOne is highlighting strong momentum across its deep and diverse solid tumor portfolio at ASCO, with seven unique assets featured in three oral presentations and eight posters. These data span both in-line and pipeline therapies, including results demonstrating the differentiated profile of PD-1 inhibitor TEVIMBRA® (tislelizumab) across lung and gastrointestinal cancers, as well as in combination with the novel HER2-targeting agent ZIIHERA® (zanidatamab). The Company’s development superhighway is accelerating progress across all stages of development, generating compelling clinical data that support the potential of these therapies to reshape treatment in areas of high unmet need.

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said:

“At ASCO 2026, we are demonstrating the strength of BeOne’s science, the scale of our pipeline, and the speed at which we are delivering innovation for patients. With multiple programs moving simultaneously toward pivotal trials, we are building durable disease leadership across breast, gynecologic, lung and gastrointestinal cancers – areas where substantial unmet patient need remains.”

Key data presentations across our solid tumor programs include:

First disclosure of anti-tumor effects and safety/tolerability profile of the highly selective CDK4 inhibitor BGB-43395 Phase 1 treatment data in first-line HR-positive/HER2-negative breast cancer.

Rapid oral presentation on BG-C9074, a promising B7-H4-targeting ADC, with Phase 1 dose escalation and safety expansion data.

Rapid oral presentation on BGB-B2033, a potentially first-in-class GPC3 x 4-1BB bispecific antibody, with first clinical data of a Phase 1 study in heavily pre-treated hepatocellular carcinoma patients.

Rapid oral presentation with a PD-L1 subgroup analysis of the HERIZON-GEA-01 trial in which TEVIMBRA in combination with ZIIHERA and chemotherapy demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) in patients with HER2+ gastroesophageal adenocarcinoma, irrespective of PD-L1 expression (in partnership with Jazz Pharmaceuticals).

Investor webcast to highlight pipeline data at ASCO

BeOne will host an investor webcast on June 1, 2026, at 7:00 PM CDT/8:00 PM EDT, led by John V. Oyler, Co-Founder, Chairman, and CEO, alongside the Company’s leadership team and invited key opinion leaders. The webcast will review clinical and corporate highlights from ASCO, provide updates on BeOne’s global R&D pipeline and platforms, and discuss the strategic priorities and execution capabilities driving the Company’s long-term growth.

Webcast access details are available in the Investors section of BeOne’s website at http://ir.beonemedicines.com, https://hkexir.beonemedicines.com, and https://sseir.beonemedicines.com. An archived webcast will be available on the Company’s website.

Full list of BeOne’s presentations at ASCO:

Hematology

BRUKINSA® (Zanubrutinib)

Abstract Title

Presentation Details

Lead Author

Subsequent therapies and time to second progression-free survival events in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab in SEQUOIA

Poster Presentation: 544

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Constantine S. Tam

Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization

 

Poster Presentation: 556

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Alvaro Alencar

 

Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

Poster Presentation: 545

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Daniel A. Ermann

 

Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia

Poster Presentation: 540

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Michael Fradley

 

Real-world treatment survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States

Poster Presentation: 543

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Ryan Jacobs

 

A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States

Poster Presentation: 560

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Yucai Wang

 

Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib

Abstract Number: e19020

Ryan Jacobs

 

Risk factors for second primary malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world study

Abstract Number: e19022

Lili Zhou

Characterizing patient self-reported adherence to BTKis and symptoms in CLL/SLL using an electronic patient-reported outcomes platform

Abstract Number: e19030

Mustafa Ascha

Real-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenström macroglobulinemia

Abstract Number: e19056

Jorge Castillo

 

Sonrotoclax

Abstract Title

Presentation Details

Lead Author

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

Poster Presentation: 541

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Constantine S. Tam

Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2)

Poster Presentation: 596a

 

Session Title: Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

 

Session Date/Time: June 1, 2026, 9:00 AM-12:00 PM CDT

Mazyar Shadman

 

Efficacy of sonrotoclax vs pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: An indirect comparison

Abstract Number: e19050

 

Alvaro Alencar

Solid Tumors

BGB-43395 (CDK4i)

Abstract Title

Presentation Details

Lead Author

First disclosure of frontline treatment with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer: A phase 1 safety expansion

 

Poster Session: 180

 

Session Title: Poster Session - Breast Cancer - Metastatic

 

Session Date/Time: June 1, 2026, 1:30-4:30 PM CDT

Shom Goel

BG-C9074 (B7-H4-targeting ADC)

Abstract Title

Presentation Details

Lead Author

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

Rapid Oral Abstract: 3013

 

Session Title: Rapid Oral Abstract Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

 

Session Date/Time: June 2, 2026, 9:45-11:15 AM CDT

Binghe Xu

Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4-targeting ADC) from pharmacokinetics, efficacy and safety perspectives

Poster Session: 166

 

Session Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

 

Session Date/Time: May 30, 2026, 1:30-4:30 PM CDT

Hugh Giovinazzo

BGB-B2033 (GPC3x4-1BB bispecific antibody)

Abstract Title

Presentation Details

Lead Author

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

Rapid Oral Abstract: 3016

 

Session Title: Rapid Oral Abstract Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

 

Session Date/Time: June 2, 2026, 9:45-11:15 AM CDT

Hong Jae Chon

 

TEVIMBRA® (tislelizumab) and ZIIHERA® (zanidatamab)

Abstract Title

Presentation Details

Lead Author

Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: PD-L1 subgroup analysis from HERIZON-GEA-01

 

Rapid Oral Abstract: 4010

 

Session Title: Rapid Oral Abstract

Session – Gastrointestinal

Cancer-Gastroesophageal,

Pancreatic, and Hepatobiliary

 

Session Date/Time: June 1, 2026, 1:15-2:45 PM CDT

SunYoung Rha

 

Characterization and management of gastrointestinal adverse events with zanidatamab + chemotherapy ± tislelizumab in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: Analysis from HERIZON-GEA-01

Poster Presentation: 25

 

Session Title: Poster Session –

Gastrointestinal Cancer-

Gastroesophageal, Pancreatic,

and Hepatobiliary

 

Session Date/Time: May 30, 2026, 9

AM-12:00 PM CDT

Elena Elimova

TEVIMBRA® (tislelizumab)

Abstract Title

Presentation Details

Lead Author

RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy

Poster Presentation: 533

 

Session Title: Poster Session - Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

 

Session Date/Time: May 31, 2026, 9:00 AM-12:00 PM CDT

Gustavo Schvartsman

Quality-adjusted survival comparison for tislelizumab + chemotherapy (CT) versus placebo + CT as first-line treatment in gastric/gastroesophageal junction adenocarcinoma patients with peritoneal metastasis: Long-term follow-up from RATIONALE-305

Poster Presentation: 17

 

Session Title: Poster Session - Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary

 

Session Date/Time: May 30, 2026, 9:00 AM-12:00 PM CDT

Rutika Mehta

A novel Bayesian approach for assessing associations between ECOG performance status and patient-reported outcomes in patients with gastric or gastroesophageal junction adenocarcinoma: Post hoc analysis from the RATIONALE-305 trial

Abstract Number: e16044

Marcia Cruz-Correa

 

Ociperlimab

Abstract Title

Presentation Details

Lead Author

Exploratory biomarker analysis of ociperlimab plus tislelizumab in patients with PD-L1-positive non-small cell lung cancer in AdvanTIG-105

Poster Session: 361

 

Session Title: Poster Session - Developmental Therapeutics - Immunotherapy

 

Session Date/Time: May 30, 2026, 1:30-4:30 PM CDT

Jun Zhang

BGB-A3055 (anti-CCR8)

Abstract Title

Presentation Details

Lead Author

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Poster Session: 313

 

Session Title: Poster Session - Developmental Therapeutics - Immunotherapy

 

Session Date/Time: May 30, 2026, 1:30 PM-4:30 PM CDT

Judith Raimbourg

Full list of BeOne’s presentations at EHA:

Zanubrutinib

Abstract Title

Presentation Details

Lead Author

Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 years) treatment naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial

Publication Number: PS1703

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Alessandra Tedeschi

Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab

Publication Number: PF601

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Mazyar Shadman

Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17

Publication Number: PS1718

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Talha Munir

Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: Post hoc analysis from the ALPINE trial

Publication Number: PS2492

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Nicole Lamanna

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE

Publication Number: PF1398

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

 

Loic Ysebaert

Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy

Publication Number: PF618

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Jing-Zhou Hou

Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia: Real-world evidence from the United States

Publication Number: PS2516

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Prashant Kapoor

Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia

Publication Number: PS1710

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Nakhle Saba

Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States

Publication Number: PF608

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Ryan Jacobs

A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States

Publication Number: PS2040

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Yucai Wang

Clinical outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the United States

Publication Number: PF958

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Javier Munoz

Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia

Publication Number: PS2515

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Rhys Williams

Treatment burden among patients aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma

Publication Number: PF605

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Daniel Ermann

Real-world effectiveness and safety of zanubrutinib in Waldenström macroglobulinemia: Results from the Belgian WIZARD study

Abstract Number: PB3600

 

Willem Daneels

Real-world experience with zanubrutinib in chronic lymphocytic leukaemia - patient profile, treatment patterns, and safety: Preliminary analysis of French ROZALY study

Abstract Number: PB2898

 

Florian Bouclet

BRUMIZE: Real-world zanubrutinib use and preliminary safety in R/R marginal zone lymphoma in Europe

Abstract Number: PB3632

 

Côme Bommier

Indirect comparison of zanubrutinib vs acalabrutinib and ibrutinib efficacy in patients with treatment-naïve chronic lymphocytic leukemia

Abstract Number: PB2895

Mazyar Shadman

Patient-reported outcomes and disease progression in chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic literature review and gap analysis

Abstract Number: PB2909

Loic Ysebaert

Understanding patients' perspectives and preferences regarding first-line chronic lymphocytic leukemia treatment across Europe

Abstract Number: PB2934

Lydia Scarfò

Number of deaths avoided with use of zanubrutinib versus ibrutinib for the treatment of chronic lymphocytic leukemia in Europe

Abstract Number: PB2944

Talha Munir

Real-world intravenous immunoglobulin utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with venetoclax plus obinutuzumab vs zanubrutinib

Abstract Number: PB2915

Nicole Lamanna

Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

Abstract Number: PB2901

 

Daniel A. Ermann

Exploring the patient and hematologist preference of treatment characteristics for chronic lymphocytic leukemia: A qualitative study in Europe

Abstract Number: PB4474

Lydia Scarfò

Sonrotoclax

Abstract Title

Presentation Details

Lead Author

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

Publication Number: S145

 

Session: s424 Prognostication and first line therapy in CLL

 

Session Date/Time: June 12, 2026

17:15 - 18:30 CEST

Chan Y. Cheah

Updated safety and efficacy of all-oral sonrotoclax + zanubrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including patients with del(17p)/TP53

Publication Number: PS1697

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Stephen S. Opat

Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: Results from a phase 1/1b study

Publication Number: PF933

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Jacob D. Soumerai

Phase 1/2 study of sonrotoclax (BGB-11417) monotherapy in Bruton tyrosine kinase inhibitor–pretreated relapsed/refractory mantle cell lymphoma: A Chinese subpopulation analysis

Publication Number: PF961

 

Session: Poster Session 1

 

Session Date/Time: June 12, 2026, 6:45-7:45 PM CEST

Yuqin Song

Sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2)

Abstract Number: PB2966

Mazyar Shadman

Efficacy of sonrotoclax versus pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: An indirect comparison

Abstract Number: PB3626

 

Toby A. Eyre

Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization

Abstract Number: PB3617

Toby A. Eyre

Risk of tumor lysis syndrome among venetoclax-treated patients with chronic lymphocytic leukemia or mantle cell lymphoma: A real-world study

Abstract Number: PB2896

Alessandra Ferrajoli

BGB-16673

Abstract Title

Presentation Details

Lead Author

BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A phase 1 CaDAnCe-101 study update

Publication Number: S152

 

Session: s449 Novel therapies in relapsed/refractory CLL

 

Session Date/Time: June 14, 2026

11:00 - 12:15 CEST

Stephan Stilgenbauer

Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study

Publication Number: PS1693

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Irina Mocanu

BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory Waldenström macroglobulinemia: A phase 1 CaDAnCe-101 study update

Publication Number: PS2033

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Judith Trotman

BGB-16673, a Bruton tyrosine kinase degrader, has low risk of CYP3A-mediated drug-drug interaction (DDI): Phase 1 absorption, distribution, metabolism, and excretion and DDI study results

Publication Number: PS1711

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Judith Trotman

BGB-16673 versus idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: The phase 3 CaDAnCe-302 trial

Abstract Number: PB2925

 

Paolo Ghia

Tislelizumab

Abstract Title

Presentation Details

Lead Author

Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: Ancillary analyses of LYSA phase 2 TIRHOL study BGB-A317-210

Publication Number: PS2028

 

Session: Poster Session 2

 

Session Date/Time: June 13, 2026, 6:45-7:45 PM CEST

Hervé Ghesquières

About BRUKINSA® (zanubrutinib)

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing and the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

About BEQALZI™ (sonrotoclax)

BEQALZI™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. BEQALZI has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.

About BGB-16673

BGB-16673 is a foundational and potential first-in-class and best-in-class Bruton’s tyrosine kinase (BTK) degrader for the treatment of B-cell malignancies. With 1,100+ patients dosed to date in an extensive global clinical development program, BGB-16673 is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, BGB-16673 is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted BGB-16673 PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

About ZIIHERA (zanidatamab)

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.1

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

ZIIHERA is a registered trademark of Zymeworks BC Inc.

About TEVIMBRA (tislelizumab)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.

Select Important Safety Information for BRUKINSA® (zanubrutinib)

Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Please see full U.S. Prescribing Information including U.S. Patient Information.

Select Important Safety Information for BEQALZITM (sonrotoclax)

Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

Please see full Prescribing Information.

Select Important Safety Information for TEVIMBRA

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

The information provided in this press release is intended for a global audience. Product indications vary by region.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s ability to advance future regiments and lead in hematology; BeOne’s ability to build durable disease area leadership in solid tumors; BeOne’s clinical development plans for various programs; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

____________________

1 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521195975/en/

Permalink

https://aetoswire.com/en/news/2105202655216

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com